---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219398"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-05-12T20:07:51+00:00"
generated_at: "2026-05-12T21:24:38.687659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial

## Summary
- MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.
- In severe FSGS subgroup, MZE829 achieved 61.8% mean uACR reduction; in non-diabetic AMKD, 48.6% reduction.
- Cash $362.9M at March 31, 2026; April 2026 raised ~$150M in offering plus $20M milestone from Shionogi; runway into 2029.
- Net loss $24.2M ($0.45/share) vs $32.8M ($1.15) YoY; license revenue $20M; R&D $34.1M, G&A $12.4M.
- MZE782 Phase 2 in PKU to start mid-2026 with topline data in 2027; Phase 2 in CKD expected H2 2026.

## SEC filing metadata
- accession: 0001193125-26-219398
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-05-12T20:07:51+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/0001193125-26-219398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219398
- JSON: https://secwatch.observer/filing/0001193125-26-219398.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.